Publications:

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer.

Cancers

Collins, Denis M DM; Conlon, Neil T NT; Kannan, Srinivasaraghavan S; Verma, Chandra S CS; Eli, Lisa D LD; Lalani, Alshad S AS; Crown, John J

Publication Date: 2019-05-28

Variant appearance in text: HER2: V773L

PubMed Link: 31141894

Variant Present in the following documents:

• Main text
• cancers-11-00737.pdf

View BVdb publication page

Computational algorithms for in silico profiling of activating mutations in cancer.

Cellular And Molecular Life Sciences : Cmls

Jordan, E Joseph EJ; Patil, Keshav K; Suresh, Krishna K; Park, Jin H JH; Mosse, Yael P YP; Lemmon, Mark A MA; Radhakrishnan, Ravi R

Publication Date: 2019-07

Variant appearance in text: HER2: V773L

PubMed Link: 30982079

Variant Present in the following documents:

• Main text

View BVdb publication page

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants.

Plos One

Verma, Sharad S; Goyal, Sukriti S; Kumari, Anchala A; Singh, Aditi A; Jamal, Salma S; Grover, Abhinav A

Publication Date: 2018

Variant appearance in text: HER-2: V773L

PubMed Link: 29389942

Variant Present in the following documents:

• Main text
• pone.0190942.pdf

View BVdb publication page